Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Future Medicinal Chemistry|March 25, 2011
Label-free screening assays: a strategy for finding better drug candidatesCharles A LunnCurrent Topics in Medicinal Chemistry|April 8, 2010
Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonistsCharles A LunnCurrent Topics in Medicinal Chemistry|February 26, 2013
TRP channels as targets for therapeutic intervention in obesity: focus on TRPV1 and TRPM5R Kyle Palmer, Charles A LunnExpert Opinion on Therapeutic Targets|September 20, 2006
Targeting the CB2 receptor for immune modulationCharles A Lunn, Eva-Pia Reich, Loretta BoberExpert Review of Molecular Diagnostics|March 28, 2008
KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation?Chuan-Chu Chou, Charles A Lunn, Nicholas J MurgoloJournal of Biomolecular Screening|January 28, 2009
Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter beta-arrestin assayDebra McGuinness, Asra Malikzay, Richard Visconti, et al.Journal of Biomolecular Screening|May 16, 2008
Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assayYan Hou, Debra E McGuinness, Andrew J Prongay, et al.Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studiesBrian J Lavey, Joseph A Kozlowski, R William Hipkin, et al.Immunopharmacology and Immunotoxicology|December 14, 2007
Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone lossCharles A Lunn, Jay Fine, Alberto Rojas-Triana, et al.Journal of Biomolecular Screening|December 19, 2009
Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assayErik F Langsdorf, Asra Malikzay, William A Lamarr, et al.Pageof 2